News

Both regions experience disproportionately high HIV case numbers due to social stigmas and isolation.

But the Minnesota governor and Kamala Harris' running mate was endorsed by the United Auto Workers and other unions soon after this morning's announcement that he was her VP pick.

The results of an international study highlight the significant impact of the Arexvy vaccine in fostering robust immune responses.

Incorporating hospice care into Medicare Advantage didn’t work out, and CMS is looking to identify low-quality providers.

Here’s what you missed this week on Managed Healthcare Executive.

Adults with heart failure with preserved ejection fraction and obesity reported a 38% overall decrease in heart failure outcomes such as hospitalization and death when compared with placebo.

Long-acting HIV treatments could be the key to diminishing HIV cases and getting Medicaid beneficiaries the help they need.

This is the latest funding announcement made by the Health Resources and Services Administration’s Enhancing Maternal Health Initiative.

The authors say their findings should not change women’s calculations about double, or bilateral mastectomy, which physicians generally discourage.

New research expands on previous knowledge that breast cancer survivors are more at risk for depression than people without breast cancer.

Artificial intelligence gains foothold in the emergency room as a note-taking aid.

Intermountain Health leveraged a self-service data platform that used algorithms to identify chronic kidney disease patients and stratify them based on gaps in care.

Here’s what you missed this week on Managed Healthcare Executive.

Today, the clade 2b outbreak has reached alarming proportions, with over 94,000 confirmed cases reported across 117 countries, including significant numbers in the U.S. and Brazil, and up to 103 deaths. The virus has been found to affect younger men who have sex with men, who are linked to high rates of HIV co-infection.

Juan Michael Porter II, a prominent healthcare journalist and HIV advocate, spoke to MHE about keeping HIV/AIDS a priority and the dynamics of funding programs and pharmaceutical pricing

Keri Althoff, Ph.D., discusses how a model developed at Johns Hopkins can assess the comorbidities that patients with HIV may face by 2030.

Improving equity for people with HIV requires health leaders to recognize that patients have different risk factors, Keri Althoff, Ph.D., of Johns Hopkins says.

Phase 3 trials reported at the International AIDS Society meeting this week show no infections among those randomly assigned to twice-year injections of lenacapavir and no reason to be worried about safety,.

The HIV vaccine field has recently faced setbacks with trials like PrepVacc, Mosaico and Imbokodo ending early due to lack of preventive efficacy. Although there have been challenges, scientists have made discoveries showing that the immune system can be prepared to fight HIV with special antibodies.

An overview of the complex relationships between herpes simplex virus, human papillomavirus, cytomegalovirus and HIV.

Younger transgender and gender diverse individuals see a greater stigma around PrEP, but experts are still unsure why.

Healthcare journalist, HIV advocate and educator Juan Michael Porter II discussed moderating the "Future of Science" session at the International AIDS Society's AIDS 2024 meeting in Munich, Germany, as well as addressing "founder's syndrome" in AIDS organizations and the inclusivity of the event.

Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis, which accounted for nearly one-fifth of all pediatric hospitalizations in the U.S. before the pandemic.

At the 25th annual international AIDS Conference in Munich, Germany, a group of international experts discussed the impact of HIV-related stigma and discrimination on efforts to end the HIV pandemic as a public health threat by 2030.

When it comes to preventing and treating patients with HIV/AIDS, experts say to look towards the youth.

The number of biologics approved as treatments for psoriasis has proliferated but the FDA has approved just four for use in children. Six biologics for pediatric psoriasis are in various stages of development.

Dante J. Pieramici, M.D., of the California Retina Research Foundation, explains changes made to the Susvimo port delivery system that are designed. to prevent the septum dislodgment that led to Genentech pulling the product off the market.

Inequalities throughout the world in treatment and prevention of HIV are not being addressed, with infection rates rising in the Middle East and north Africa, Eastern Europe and central Asia and Latin America.